Alteration of Tremor Dominant and Postural Instability Gait Difficulty Subtypes During the Progression of Parkinson’s Disease: Analysis of the PPMI Cohort

Jeong Won Lee¹, Yoo Sung Song²*, Hyeyun Kim³, Bon D. Ku³ and Won Woo Lee²,⁴

¹ Department of Nuclear Medicine, International St. Mary’s Hospital, Catholic Kwandong University College of Medicine, Incheon, South Korea, ² Department of Nuclear Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea, ³ Department of Neurology, International St. Mary’s Hospital, Catholic Kwandong University College of Medicine, Incheon, South Korea, ⁴ Medical Research Center, Institute of Radiation Medicine, Seoul National University, Seoul, South Korea

Background: Classifying PD into tremor dominant (TD) and postural instability gait difficulty (PIGD) subtypes may have several limitations, such as its diagnostic inconsistency and inability to reflect disease stage. In this study, we investigated the patterns of progression and dopaminergic denervation, by prospective evaluation at regular time intervals.

Methods: 325 PD dopamine replacement drug-naïve patients (age 61.2 ± 9.7, M:F = 215:110) were enrolled. Patients were grouped into TD, indeterminant, and PIGD subtypes. Clinical parameters and I-123 FP-CIT SPECT images of each groups were analyzed and compared at baseline, 1, 2, and 4 years of follow up periods.

Results: Baseline I-123 FP-CIT uptakes of the striatum were significantly higher in the TD group compared with the indeterminant group and PIGD group (p < 0.01). H & Y stage and MDS-UPDRS part III scores of the indeterminant group were significantly worse at baseline, compared with the TD and PIGD groups (p < 0.001 and p < 0.01, respectively), and MDS-UPDRS part II scores of the indeterminant group were significantly worse than the PIGD group (p < 0.001). There were no other significant differences of age, gender, weight, duration of PD, SCOPA-AUT, MOCA, usage of dopamine agonists, and levodopa equivalent daily doses at baseline. After 4 years of follow up, there were no differences of I-123 FP-CIT uptakes or clinical parameters, except for the MDS-UPDRS part II between the TD and indeterminant group (p < 0.05). The motor-subtypes were reevaluated at the 4 years period, and the proportion of patients grouped to the PIGD subtype increased. In the reevaluated PIGD group, MDS-UPDRS part II score (p < 0.001), SCOPA-AUT (p < 0.001), the proportion of patients who developed levodopa induced dyskinesia were higher than the reevaluated TD group, and the striatal I-123 FP-CIT uptakes were significantly lower (p < 0.01).
INTRODUCTION

Parkinson’s disease (PD) is a neurodegenerative disorder that is mainly known for the deterioration of one’s motor functions. However, it is also accompanied by a broad spectrum of non-motor symptoms such as cognitive decline, mood disorder, sleep disorder, and autonomic dysfunction (1), and each PD patient presents with heterogenous symptoms and progression rates (2). Due to the various and complex manifestations of PD, the pathophysiology of each respective symptoms has been one of the major fields of investigation. For instance, the progression of gait disturbance is known to be associated with nigrostriatal dopaminergic denervation, while the progression of other non-motor symptoms such as autonomic dysfunction and cognitive deterioration is known to be associated with extrastriatal pathologies (3). Thus, identifying the homogenous groups of PD and categorizing into subtypes have been of interest for decades.

Previous studies have proposed that classifying PD into homogenous motor subtypes would be of value, by providing a better understanding of the pathology, prognosis, progression pattern, and the key to develop proper treatment strategies (4). Analysis of the motor symptoms came to define the subtypes of PD into the tremor dominant (TD) type and the postural instability gait difficulty (PIGD) type (5), and the clinical outcomes of the two subtypes have been investigated. However, there are some controversies on this topic, while some report the TD subtype to have a better prognosis and mild disease progression rate compared with the PIGD subtype, while others claim no differences of long term outcomes (6–15). Regarding to pathologies, several studies have depicted different patterns of striatal dopaminergic denervation between the two subtypes (16, 17), and some studies investigated the patterns of dopamine denervation in different motor subtypes of PD, via [I-123] N-β-carbomethoxy- 3β-(4-iodophenyl) nortropane (I-123 FP-CIT) SPECT imaging. However, they have also have failed to show a consistent description. Some described higher striatal I-123 FP-CIT uptake in the TD subtype, while some described no significant differences between the TD and PIGD subtypes (18–21). Therefore, there still remains several unclarified issues on the progression and dopaminergic denervation of PD, in a subtype-based aspect.

The aim of our study was to compare the progressive pattern and dopaminergic denervation of PD between different subtypes, by evaluating the clinical symptoms, and I-123 FP-CIT SPECT images at regular time intervals. Loss of dopaminergic innervation and the severity of symptoms are known to worsen throughout the lifetime in a non-linear, exponential pattern (22, 23). Therefore, the functional decline and disease progression should be investigated in a prospective approach. In our study, patients were periodically evaluated in a prospective PD cohort, under the assumption that different subtypes may have different progression patterns and paces. Clinical parameters and I-123 FP-CIT SPECT image findings were evaluated and quantified upon a subgroup-based analysis, on a regular basis at baseline, 1, 2, and 4 years of follow up. Finally, the clinical subtypes of the whole group of patients were reevaluated after 4 years of follow up, to observe any changes of main motor phenotypes.

MATERIALS AND METHODS

Patients

Subject data were downloaded from the Parkinson’s Progression Markers Initiative (PPMI) database (http://www.ppmi-info.org) in April, 2018. Three hundred and twenty-five PD patients (age 61.2 ± 9.7, M:F = 215:110) were enrolled. The inclusion criteria were as follows: a diagnosis of PD for 2 years or less at the time of screening, dopamine transporter (DAT) deficit on baseline I-123 FP-CIT SPECT images, age 30 years or more, Hoehn and Yahr (H & Y) stage I or II at baseline. Patients had at least two or more I-123 FP-CIT SPECT images acquired during follow up at 1, 2, and 4 years of time points. Movement Disorder Society-Unified Parkinson’s disease rating scale (MDS-UPDRS) scores, H & Y stages, levodopa equivalent daily doses (LEDD), Scale for Outcomes in Parkinson’s disease-Autonomic (SCOPA-AUT), and Montreal Cognitive Assessment (MOCA) were evaluated at baseline, 1, 2, and 4 years of follow up. Patients on any kinds of PD related medications on baseline were excluded. Patients were asked to withhold their PD related medication for 12 h before motor assessment. The patient group was subdivided into tremor dominant (TD), indeterminant, and postural instability/gait difficulty (PIGD) subtypes according to TD and PIGD scores based on UPDRS items. In short, the ratio of the mean tremor score to the mean PIGD scores was used to define TD patients (ratio ≥1.5), PIGD patients (ratio ≤1), and indeterminate patients (ratios >1.0 and <1.5) (5). All methods were performed in accordance with the relevant guidelines and regulations. Written informed consent for all clinical data were obtained of all PPMI participants, and all subjects gave written informed consent in accordance with the 1964 Declaration of Helsinki and its later amendments. The study was approved in all participating sites, respectively, by each local Institutional review boards.

Conclusion: There are no significant differences of symptoms and dopaminergic innervation between the TD and PIGD group after a certain period of follow up. Significant portion of patients switched from the TD subtype to the PIGD subtype during disease progression, and had a worse clinical prognosis.

Keywords: Parkinson’s disease, tremor dominant, postural instability gait difficulty, PPMI, I-123 FP-CIT SPECT
I-123 FP-CIT SPECT Analysis
I-123 FP-CIT SPECT scans were acquired 4 ± 0.5 h after I-123 FP-CIT injection (111–185 MBq). Images were reconstructed iteratively, without any filtering. In order to maintain a uniform dataset from multiple institutions, the core imaging lab of PPMI performs quality controls, such as phantom studies, validation of acquisition protocols, and standardization of image processing procedures. Respective institutions also received technical setup visits from the core imaging lab before study enrollment. Image analysis were done with the PMOD software (PMOD Technologies, Zurich, Switzerland). Specific binding ratios [SBRs, (target region/reference region)-1] of each caudate and putamen were acquired with the occipital cortex as a reference tissue. Minimum SBR values among the bilateral striatal regions were selected for analysis.

Statistical Analysis
Medcalc version 18.9.1 (MedCalc Software, Belgium) was used for analysis. Demographic factors and striatal SBRs between the groups were compared by one-way ANOVA or Kruskal-Wallis test.

RESULTS

Demographic Characteristics
Among our cohort of 325 patients, 221 patients were classified as TD (68.0%), 29 patients as indeterminant type (8.9%), and 75 patients as PIGD type (23.1%) at baseline. Baseline demographic and clinical characteristics are presented in Table 1. H & Y stage and MDS-UPDRS part III scores of the indeterminant group were significantly worse at baseline, compared with the TD and PIGD groups ($P < 0.001$ and $P < 0.01$, respectively), and MDS-UPDRS part II scores of the indeterminant group were significantly worse than the PIGD group ($P < 0.001$). The SBRs of the caudate and putamen were significantly lower in the indeterminant group and PIGD group compared with the TD group ($P < 0.01$ for both caudate and putamen). No significant differences were observed in age, gender, weight, duration of PD, SCOPA-AUT, MOCA, usage of dopamine agonists, and LEDD between any groups.

Serial Changes of SBRs During 4 Years of Follow Up
Caudate SBRs of the indeterminate and PIGD groups were significantly lower than that of the TD group until 1 year follow up ($P < 0.01$), and at 2 years of follow up the difference was significant in between the PIGD group and TD group only ($P < 0.01$). There were no significant differences between any groups at 4 years of follow up. Putaminal SBRs of the PIGD group were significantly lower than that of the TD group until 1 year follow up ($P < 0.05$), and there was a significant difference between the PIGD group and TD group, at 2 years of follow up ($P < 0.05$). There were no significant differences between any groups at 4 years of follow up (Table 2).

Serial Changes of Clinical Parameters During 4-Years of Follow Up
Serial changes of the clinical parameters of each group were analyzed at baseline, 1, 2, and 4 years of follow up (Table 3). H & Y stage of the indeterminant group was significantly higher than the TD and PIGD groups at 2 years of follow up ($P < 0.01$), but there were no significant differences at 4 years of follow up. MDS-UPDRS part II scores of the indeterminant group were significantly higher than the TD group until 4 years of follow up ($P < 0.05$), but there were no significant differences of the MDS-UPDRS part III scores between any groups at 4 years of follow up. The SCOPA-AUT of the indeterminant group was significantly higher than the TD group at 1 year follow up, but there were no significant differences of SCOPA-AUT between any groups at 2 and 4 years of follow up. There were no significant differences of MOCA scores between any groups at throughout the follow up. There was a significantly higher portion of LID development in the indeterminant group after 4 years of follow up, with a higher score of MDS-UPDRS part IV question 4.1 (time spent with dyskinesias) (Table 4).

Reevaluation of Clinical Subtypes After 4 Years of Follow Up
TD and PIGD scores were reevaluated after 4 years of follow up, and the patients were reevaluated into TD, indeterminant, and PIGD subtypes. The total proportion of TD group decreased from 68.0% at baseline to 44.6% at 4 years, and the proportion of PIGD group increased from 23.1% at baseline to 44.2% at 4 years. 77.8% of the indeterminant group altered to PIGD group (Table 5). Based on the reevaluated clinical subtypes, the clinical parameters at 4 years follow up were compared between each group (Table 6). MDS-UPDRS part II score, SCOPA-AUT were significantly higher in the PIGD group compared with the TD group ($P < 0.001$, both). Proportion of patients who developed levodopa induced dyskinesia was higher in the PIGD group than the TD group at 4 years of follow up, with a higher MDS-UPDRS 4.1 score ($P <0.01$). SBRs of the caudate and putamen were significantly lower in the PIGD group than the TD group ($P < 0.01$, both).

DISCUSSION
There have been several previous studies that examined the prognoses and clinical courses of TD and PIGD subtypes. However, there are controversies on whether the clinical progression and severity of the PIGD group is worse or not, and also on whether there are any differences of the pace of dopaminergic denervation between the TD subtype and the PIGD subtype. This may be due to the relatively small number of patients, inconsistent periods of disease evaluation, and irregular timepoints of I-123 FP-CIT SPECT image acquisition. In our study, we demonstrated the sequential changes of clinical parameters and I-123 FP-CIT uptakes at baseline, and at regular periods of 1, 2, and 4 years of follow up. Additionally, we demonstrated that the clinical subtypes may also change in a large proportion, during the progression of PD. MDS-UPDRS
TABLE 1 | Baseline patient characteristics.

|                          | TD subtype (n = 221) | Indeterminant subtype (n = 29) | PIGD subtype (n = 75) | P-value |
|--------------------------|----------------------|--------------------------------|-----------------------|---------|
| Age at PD onset (years)  | 61.2 ± 9.6           | 62.2 ± 9.1                     | 60.5 ± 10.1           | 0.71    |
| Gender (Male: Female)    | 144: 78              | 23: 6                          | 48: 17                | 0.15    |
| Weight (kg)              | 82.2 ± 17.8          | 82.8 ± 12.7                    | 79.5 ± 16.6           | 0.51    |
| Duration of symptoms until study enroll (months) | 24.7 ± 23.4 | 29.4 ± 21.6 | 18.7 ± 12.4 | 0.05 |
| Caudate SBRs             | 1.9 ± 0.6a           | 1.6 ± 0.3b                     | 1.7 ± 0.5b            | <0.01   |
| Putaminal SBRs           | 0.7 ± 0.2a           | 0.6 ± 0.1b                     | 0.6 ± 0.2b            | <0.01   |
| H&Y staging              | 1.5 ± 0.5a           | 1.9 ± 0.4b                     | 1.6 ± 0.5a            | <0.001  |
| MDS-UPDRS Part II score  | 5.9 ± 3.6a           | 9.4 ± 4.5b                     | 8.0 ± 4.3b            | <0.001  |
| MDS-UPDRS Part III score | 20.1 ± 8.6a          | 25.2 ± 8.9b                    | 20.1 ± 8.0a           | <0.01   |
| SCOPA-AUT                | 8.4 ± 5.8            | 10.6 ± 5.0                     | 9.4 ± 5.9             | 0.09    |
| MOCA                     | 27.2 ± 2.2           | 26.3 ± 2.7                     | 27.2 ± 2.4            | 0.14    |
| Use of dopamine agonist, % | 56.6                 | 51.7                           | 61                    | 0.63    |
| Average LEDD at 48 months (g) | 1264.0 ± 1288.8 | 1377.7 ± 1414.8 | 1264.2 ± 1191.6 | 0.90   |

For a particular variable, values with different superscripts indicate statistically significant difference.

TABLE 2 | SBRs of T-123 FP-CIT during follow up.

|                          | TD subtype | Indeterminant subtype | PIGD subtype | P-value |
|--------------------------|------------|-----------------------|--------------|---------|
| CAUDATE                  |            |                       |              |         |
| Baseline                 | 1.9 ± 0.3a (221) | 1.6 ± 0.3b (29) | 1.7 ± 0.3b (75) | <0.01  |
| 1 year                   | 1.7 ± 0.3a (202) | 1.4 ± 0.2b (25) | 1.5 ± 0.3b (67) | <0.01  |
| 2 years                  | 1.6 ± 0.3a (196) | 1.3 ± 0.4b (28) | 1.4 ± 0.3b (70) | <0.01  |
| 4 years                  | 1.4 ± 0.5 (173) | 1.1 ± 0.4b (22) | 1.2 ± 0.5 (64) | <0.05  |
| PUTAMEN                  |            |                       |              |         |
| Baseline                 | 0.7 ± 0.2a (221) | 0.6 ± 0.1b (29) | 0.6 ± 0.2b (75) | <0.01  |
| 1 year                   | 0.6 ± 0.2a (202) | 0.5 ± 0.2b (25) | 0.5 ± 0.2b (67) | <0.05  |
| 2 years                  | 0.6 ± 0.2a (196) | 0.5 ± 0.2b (28) | 0.5 ± 0.2b (70) | <0.05  |
| 4 years                  | 0.5 ± 0.2 (173) | 0.4 ± 0.2b (22) | 0.4 ± 0.2b (64) | <0.05  |

For a particular variable, values with different superscripts indicate statistically significant difference. The values in parentheses represent the number of patients.

part II scores and striatal SBRs were worse in the PIGD group than the TD group at baseline, but there were no significant differences of the H & Y staging, MDS-UPDRS part III scores, MOCA scores, MDS-UPDRS part IV question 4.1 (time spent with dyskinesias), and SCOPA-AUT at baseline between the TD group and the PIGD group. Moreover, there were no differences of any parameters between the two subtypes after 4 years of follow up. This finding corresponds to the fact that the tremor dominant feature is not related with a favorable long term prognosis (7, 13). In conclusion, our results showed no significant differences of any important clinical parameters between TD and PIGD groups after a certain period of time. This may be due to the regular periodic assessment during the follow of 4 years, but also because of the changes of motor subtypes during the progression of PD, which will be discussed in the next paragraph.

In our patient population, the proportion of PIGD patients increased after 4 years of follow up. It has been previously suggested that the subtype may change during the course of PD, and the transition of the TD subtype to the PIGD subtype suggests that motor subtypes are not different entities of PD, but are rather different stages of PD (24, 25). Our study adds evidence and several additional points of view to this stream. First of all, in regards to the progression rate, the loss of dopaminergic neurons in PD is known to progress in an exponential pattern (22, 23), which implicates a more rapid progression in the early stage of PD than the later stage. In our study, the TD subtype had higher striatal SBRs than the PIGD subtype at baseline, but the differences disappeared during the 4 years of follow up. Therefore, we also suggest that not only TD and PIGD subtypes are sequential stages of PD, but that the TD subtype has a more rapid rate of dopaminergic denervation than the PIGD subtype. Secondly, patients grouped to the TD subtype at baseline did not have a favorable prognosis. Instead, we could say that the patients who changed from the TD subtype to the PIGD subtype has a worse and faster prognosis, considering that there were no differences of symptom duration between the TD and PIGD groups prior to enrollment. Among numerous risk factors for PD, conversion of subtype may have its strength as an indicator of disease progression. Recently, it has been suggested that the conventional motor-phenotype based subtyping has several shortcomings for clinical application. As mentioned above, it is still questionable whether the subtyping is valid in predicting prognosis. Also, there may be potential confounding factors such as age, disease stage, and genetic factors that affect the reliability of subtype diagnosis at baseline (26). To overcome the limitations of TD/PIGD subtyping, recent studies performed cluster analysis with other biomarkers, and non-motor phenotypes (27, 28). According to these cluster analyses, patients grouped to the diffuse malignant subtype had a faster prognosis, but only one-third of this subtype was PIGD dominant at baseline (28). Similarly, in our study, among patients who were grouped to the PIGD subtype at 4 years, only 42% of patients were subtyped to...
TABLE 3 | Clinical parameters during follow up.

| H &Y STAGE | TD subtype | Indeterminant subtype | PIGD subtype | P-value |
|------------|------------|------------------------|--------------|---------|
| Baseline (325) | 1.5 ± 0.5a | 1.9 ± 0.4b | 1.6 ± 1.5a | 0.001 |
| 1 year (325) | 1.7 ± 0.5 | 1.9 ± 0.3 | 1.7 ± 0.6 | 0.09 |
| 2 years (325) | 1.7 ± 0.5a | 2.0 ± 0.5b | 1.8 ± 0.6a | <0.01 |
| 4 years (325) | 1.8 ± 0.5 | 2.0 ± 0.5 | 2.0 ± 0.8 | 0.06 |

| MDS-UPDRS II | TD subtype | Indeterminant subtype | PIGD subtype | P-value |
|--------------|------------|------------------------|--------------|---------|
| Baseline | 5.9 ± 3.6a (221) | 9.4 ± 4.5b (29) | 8.0 ± 4.3b (75) | <0.001 |
| 1 year | 7.5 ± 4.6a (203) | 11.0 ± 4.8b (28) | 9.0 ± 4.5 (70) | <0.001 |
| 2 years | 8.1 ± 4.7a (206) | 11.9 ± 5.3b (28) | 9.4 ± 5.6 (71) | <0.001 |
| 4 years | 10.3 ± 6.0a (204) | 13.9 ± 6.2b (26) | 11.5 ± 7.8 (73) | <0.05 |

| MDS-UPDRS III | TD subtype | Indeterminant subtype | PIGD subtype | P-value |
|---------------|------------|------------------------|--------------|---------|
| Baseline | 20.1 ± 8.5a (221) | 25.2 ± 8.9b (29) | 20.1 ± 8.5a (75) | <0.001 |
| 1 year | 22.8 ± 10.1a (203) | 27.8 ± 9.3b (28) | 23.0 ± 10.8 (70) | 0.07 |
| 2 years | 24.3 ± 11.2a (206) | 30.0 ± 11.5b (28) | 26.6 ± 12.0 (71) | <0.05 |
| 4 years | 29.8 ± 11.2a (182) | 32.5 ± 12.4b (22) | 30.9 ± 14.2 (69) | 0.57 |

| SCOPA-AUT | TD subtype | Indeterminant subtype | PIGD subtype | P-value |
|-----------|------------|------------------------|--------------|---------|
| Baseline | 8.4 ± 5.8a (221) | 10.6 ± 5.0b (29) | 9.4 ± 5.9 (75) | 0.09 |
| 1 year | 9.3 ± 7.0a (221) | 12.6 ± 7.0b (29) | 11.0 ± 6.7 (75) | <0.05 |
| 2 years | 12.1 ± 7.0a (206) | 14.1 ± 6.1b (28) | 13.1 ± 7.9 (71) | 0.30 |
| 4 years | 12.3 ± 7.0a (203) | 16.0 ± 7.4b (24) | 13.4 ± 8.5 (72) | 0.05 |

| MOCA | TD subtype | Indeterminant subtype | PIGD subtype | P-value |
|------|------------|------------------------|--------------|---------|
| Baseline | 27.2 ± 2.2a (221) | 26.3 ± 2.7b (29) | 27.2 ± 2.4 (75) | 0.14 |
| 1 year | 26.5 ± 2.7a (203) | 26.2 ± 2.8b (29) | 26.5 ± 2.6 (75) | 0.84 |
| 2 years | 26.7 ± 2.7a (203) | 25.6 ± 3.7b (28) | 26.3 ± 2.6 (71) | 0.13 |
| 4 years | 26.8 ± 3.1a (208) | 26.0 ± 4.2b (27) | 26.5 ± 3.7 (73) | 0.54 |

For a particular variable, values with different superscripts indicate statistically significant difference. The values in parentheses represent the number of patients.

TABLE 4 | Ratio of patients affected with levodopa induced dyskinesia during follow up.

| TD subtype | Indeterminant subtype | PIGD subtype | P-value |
|------------|------------------------|--------------|---------|
| 1 year | 2% (115: 2) | 6% (17: 1) | 2% (48: 1) | 0.39 |
| 2 years | 5% (161: 9) | 7% (26: 2) | 7% (83: 5) | 0.67 |
| 4 years | 8% (177: 16) | 29% (17: 7) | 18% (59: 13) | <0.01 |
| MDS-UPDRS 4.1 at 4 year | 0.1 ± 0.5a | 0.6 ± 1.2b | 0.2 ± 0.5a | <0.001 |

For a particular variable, values with different superscripts indicate statistically significant difference. The values in parentheses represent the number of patients without: and with levodopa induced dyskinesia.

TABLE 5 | Changes of subtypes, reevaluated after 4 years of follow up.

| TD at 4 years | Indeterminant at 4 years | PIGD at 4 years | Total |
|---------------|--------------------------|---------------|-------|
| TD at baseline | 82 (58.3%) | 18 (12.8%) | 41 (29.1%) | 141 |
| Indeterminant at baseline | 4 (22.2%) | 0 (0%) | 14 (77.8%) | 18 |
| PIGD at baseline | 10 (17.8%) | 6 (10.7%) | 40 (71.4%) | 56 |
| Total | 96 | 24 | 95 |

For a particular variable, values with different superscripts indicate statistically significant difference. The values in parentheses represent the number of patients without: and with levodopa induced dyskinesia.

In conclusion, our findings support the suggestion that TD and PIGD are not different subtypes of PD, but are rather different clinical stages with different disease progression features. The indeterminant group may be the transitional stage from the TD group to the PIGD group, considering that the baseline striatal SBRs, H&Y stage, and MDS-UPDRS scores of the indeterminant group were worse than the TD group. Though most of the baseline indeterminant group

the PIGD group at baseline. In conclusion, our findings support the suggestion that TD and PIGD are not different subtypes of PD, but are rather different clinical stages with different disease progression features. The indeterminant group may be the transitional stage from the TD group to the PIGD group, considering that the baseline striatal SBRs, H&Y stage, and MDS-UPDRS scores of the indeterminant group were worse than the TD group. Though most of the baseline indeterminant group
patients (77.8%) converted to the PIGD group after 4 years, baseline H & Y staging and baseline MDS-UPDRS part III scores were worse in the indeterminant group compared with the PIGD group. This may be because of the limitation of H & Y staging, that stage II does not necessarily have a severe motor disability than stage I (29). And also, the MDS-UPDRS part III is composed of more tremor related items than posture/gait related items (5).

Unlike bradykinesia and rigidity, the severity of tremor does not correlate with striatal dopaminergic denervation (30), and has been suggested to be due to abnormal neural firing of the basal ganglia (31). Assuming from our results, tremor related pathologic changes of the basal ganglia seems to precede in the early stage of PD, followed by dopaminergic denervation of the striatum in the later stage, resulting in the conversion of dominant motor features. We have utilized the SBR values from I-123 FP-CIT SPECT images as a clinical indicator of PD progression. The degree of PD pathology is usually referred to the Braak staging, which describes the spread of Lewy bodies starting from the brain stem to the neocortex. However, the I-123 FP-CIT SPECT images do not wholly reflect the pathophysiology of PD, but show dopaminergic denervation of the striatum. We have adopted the striatal SBRs as an indirect biomarker for clinical progression, since I-123 FP-CIT SPECT image findings are known to correlate with the disease severity and duration while Braak staging does not (32–34). Though it is hard to know one's Braak stage during follow up, future studies may focus on the pathophysiology contributing to the conversion of one's phenotypes during disease progression.

There are some limitations in our study. First, the I-123 FP-CIT SPECT images could have variations since the PPMI data were collected from multiple institutions. To maintain a reliable dataset, quality control was done by the core imaging lab of PPMI, as described in the operations manual (www.ppmi-info.org). Second, our study does not include the dataset of healthy controls. The PPMI only provides the baseline clinical information of the healthy control group. By comparing the deterioration of dopaminergic innervation in normal controls, we would be able to investigate the contribution of normal aging process in the progression of PD. Finally, though we have concluded that the patient groups tended to shift to the PIGD subtype, there were still some portion of patients that were inconsistent with the tendency. 22.2 and 17.8% of the baseline indeterminant group and baseline PIGD group were reevaluated as the TD group after 4 years of follow up, respectively. The pathophysiology of PD is complex and there are many factors that can affect the subtyping. Future studies may focus on the risk factors and pathologic factors that contribute to the conversion of the subtypes, with a more sophisticated analysis of the indeterminant group.

Our study revealed that there were no significant differences of motor, autonomic dysfunction, and cognition related parameters between the TD and PIGD group after 4 years of follow up. However, this was due to the conversion of motor subtypes, resulting in a transition to a higher proportion of the PIGD subtype after 4 years. Most clinical parameters were significantly worsened in the reevaluated PIGD subtype. Therefore, instead of approaching PD as predefined TD and PIGD subtypes before treatment, it would be more reasonable to consider the conversion to the PIGD subtype as a clinical indicator for poor prognosis. Additionally, our study may give a guidance to modifying treatment strategies during the progression of PD. Some drugs such as MAO-B inhibitors have been suggested to have neuroprotective effects, but has several remaining issues to be solved, such as when it becomes effective (35, 36). Our study may contribute to future studies in applying therapeutic adjustments taking consideration into initial subtypes and subtype conversion, in order to delay disease progression.

### DATA AVAILABILITY

All datasets generated for this study are included in the manuscript and/or the supplementary files.

### ETHICS STATEMENT

The PPMI study was approved by the local Institutional Review Boards of all participating sites, and written informed consent for clinical and SPECT data were obtained from each participant at enrollment. All subjects gave written informed consent in accordance with the Declaration of Helsinki and its later amendments. All methods were

---

**TABLE 6 | Comparison of clinical parameters based on the reevaluated subtypes after 4 years of follow up.**

|                    | TD subtype (n = 96) | Indeterminant subtype (n = 24) | PIGD subtype (n = 95) | P-value |
|--------------------|--------------------|-------------------------------|-----------------------|---------|
| MDS-UPDRS Part II score | 8.7 ± 5.2<sup>a</sup> | 9.9 ± 5.1                     | 12.5 ± 6.9<sup>b</sup> | <0.001  |
| MDS-UPDRS Part III score | 29.2 ± 10.5        | 31.0 ± 9.4                    | 31.4 ± 13.7           | 0.49    |
| SCOPA-AUT | 11.2 ± 5.9<sup>a</sup> | 12.7 ± 8.0                  | 14.5 ± 8.5<sup>b</sup> | <0.001  |
| MOCA   | 26.6 ± 3.1         | 26.7 ± 2.9                   | 26.9 ± 3.4            | 0.76    |
| No. of patients with LID (% of total) | 6 (6.3%) | 4 (16.7%) | 19 (20.0%) | <0.05 |
| MDS-UPDRS 4.1 | 0.1 ± 0.2<sup>a</sup> | 0.2 ± 0.5                    | 0.3 ± 0.8<sup>b</sup> | <0.01    |
| Caudate SBRs | 1.5 ± 0.5<sup>a</sup> | 1.2 ± 0.4<sup>b</sup> | 1.2 ± 0.3<sup>b</sup> | <0.01    |
| Putaminal SBRs | 0.5 ± 0.2<sup>a</sup> | 0.4 ± 0.1                    | 0.4 ± 0.2<sup>b</sup> | <0.01    |

For a particular variable, values with different superscripts indicate statistically significant difference.
performed in accordance with the relevant guidelines and regulations.

**AUTHOR CONTRIBUTIONS**

JL participated in analysis of data, drafting the text, and preparing the tables. YS participated in conception and design of the study, analysis of data, drafting the text, and preparing the tables. HK participated in study concept, data analysis. BK participated in study concept, data analysis. WL participated in study concept, drafting the text.

**FUNDING**

This study is supported by grant no 14-2016-020 from the SNUBH Research Fund.

**REFERENCES**

1. Poewe W. Non-motor symptoms in Parkinson’s disease. *Eur J Neurol*. (2008) 15(Suppl. 1):14–20. doi: 10.1111/j.1468-1331.2008.02056.x

2. Schrag A, Quinn NP, Ben-Shlomo Y. Heterogeneity of Parkinson’s disease. *J Neurol Neurosurg Psychiatry*. (2006) 77:275–6.

3. Kalia LV, Lang AE. Parkinson’s disease. *Lancet*. (2015) 386:896–912. doi: 10.1016/S0140-6736(14)63933-3

4. Sieber BA, Landis S, Koroshetz W, Bateman R, Siderowf A, Galpern WR, et al. Prioritized research recommendations from the National Institute of Neurological Disorders and Stroke Parkinson’s Disease 2014 conference. *Ann Neurol*. (2014) 76:469–72. doi: 10.1002/ana.24261

5. Stebbins GT, Goetz CG, Burn DJ, Jankovic J, Khoo TK, Tilley BC. How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson’s disease rating scale: comparison with the unified Parkinson’s disease rating scale. *Mov Disord*. (2013) 28:668–70. doi: 10.1002/mds.25383

6. van Roosmalen SM, Colas F, Martinez-Martin P, Visser M, Verbaan D, Marinus J, et al. Clinical subtypes of Parkinson’s disease. *Mov Disord*. (2011) 26:51–8. doi: 10.1002/mds.23346

7. Louis ED, Tang MX, Cote L, Alfaro B, Mejia H, Marder K. Progression of idiopathic Parkinson’s disease. *Eur J Neurol*. (2014) 21:1123–30. doi: 10.1111/cjn.2015.02898.x

8. Louis ED, Tang MX, Cote L, Alfaro B, Mejia H, Marder K. Progression of Parkinson’s disease in the early clinical stages using a data driven approach. *J Neurol Neurosurg Psychiatry*. (2005) 76:343–8. doi: 10.1136/jnnp.2003.033530

9. Oh JY, Kim YS, Choi BH, Sohn EH, Lee AY. Relationship between clinical phenotypes and cognitive impairment in Parkinson’s disease (PD). *Arch Gerontol Geriatr*. (2009) 49:351–4. doi: 10.1016/j.archger.2008.11.013

10. Raiput AH, Voh A, Raiput ML, Robinson CA, Raiput A. Course in Parkinson disease subtypes: a 39-year clinicopathologic study. *Neurology*. (2009) 73:206–12. doi: 10.1223/WNL.0b013e3181ae7af1

11. Rossi C, Frosini D, Volterrani D, De Feo P, Unti E, Nicoletti V, et al. Differences in nigro-striatal impairment in clinical variants of early Parkinson’s disease: evidence from a FP-CIT SPECT study. *Eur J Neurol*. (2010) 17:626–30. doi: 10.1111/j.1468-1331.2009.02898.x

12. Selikhova M, Williams DR, Kempster PA, Holton JL, Revesz T, Lees AJ. A classificatory approach to the clinical presentation of early Parkinson’s disease: the Motor Subtype as a Predictor of Future Working Memory Performance. *Brain*. (Pt 11):2947–57. doi: 10.1093/brain/aww234

13. Selikhova M, Williams DR, Kempster PA, Holton JL, Revesz T, Lees AJ. A classificatory approach to the clinical presentation of early Parkinson’s disease: the Motor Subtype as a Predictor of Future Working Memory Performance. *Brain*. (Pt 11):2947–57. doi: 10.1093/brain/aww234

14. Johnson AR, Bucks RS, Kane RT, Thomas MG, Gasson N, Loftus AM. Motor Subtype as a Predictor of Future Working Memory Performance in Idiopathic Parkinson’s Disease. *PLoS ONE*. (2016) 11:e0152534. doi: 10.1371/journal.pone.0152534

15. Ba F, Obaid M, Wieler M, Camicchi R, Martin WR. Parkinson disease: the relationship between non-motor symptoms and motor phenotype. *Can J Neurol Sci*. (2016) 43:261–7. doi: 10.1017/cjn.2015.328

16. Raiput AH, Sitte HH, Raiput A, Fenton ME, Pfll C, Hornykiewicz O. Globus pallidus dopamine and Parkinson disease motor subtypes: clinical and brain biochemical correlation. *Neurology*. (2008) 70 (16 Pt 2):1403–10. doi: 10.1212/01.wnl.0000285082.18969.3a

17. Jellinger KA. Postmortem studies in Parkinson’s disease—is it possible to detect brain areas for specific symptoms? *J Neural Transm*. (Suppl.) (1999) 56:1–29.

18. Spiegel J, Hellwig D, Samnick S, Jost W, Mollers MO, Fassbender K, et al. Striatal FP-CIT uptake differs in the subtypes of early Parkinson’s disease. *J Neural Transm*. (2007) 114:331–5. doi: 10.1007/s00702-006-0518-2

19. Eggert C, Kahraman D, Fink GR, Schmidt M, Timmermann L. Akinetiform and tremor-dominant Parkinson’s disease patients show different patterns of FP-CIT single photon emission computed tomography. *Mov Disord*. (2011) 26:416–23. doi: 10.1002/mds.23468

20. Isaias IU, Benti R, Cilia R, Canesi M, Marotta G, Gerundini P, et al. [123I]FP-CIT striatal binding in early Parkinson’s disease patients with tremor vs. akinetic-rigid onset. *Neuroreport*. (2007) 18:1499–502. doi: 10.1097/WNR.0b013e3282e6f9f9

21. Kaasinen V, Kinos M, Joutsjä, Seppanen M, Noponen T. Differences in striatal dopamine transporter density between tremor dominant and non-tremor Parkinson’s disease. *Eur J Nucl Med Mol Imaging*. (2014) 41:1931–7. doi: 10.1007/s00259-014-2796-5

22. Greffard S, Verny M, Bonnet AM, Beinis JY, Gallinari C, Meaume S, et al. Motor score of the Unified Parkinson Disease Rating Scale as a good predictor of Lewy body-associated neuronal loss in the substantia nigra. *Arch Neurol*. (2006) 63:584–8. doi: 10.1001/archneur.63.4.584

23. Schwarz J, Storch A, Koch W, Pogarell O, Radau PE, Tatsch K. Loss of dopamine transporter binding in Parkinson’s disease follows a single exponential rather than linear decline. *J Nucl Med*. (2004) 45:1694–7.

24. Nutt BC. Motor subtype in Parkinson’s disease: different disorders or different stages of disease? *Mov Disord*. (2016) 31:957–61. doi: 10.1002/mds.26657

25. Alves G, Larsen JP, Emre M, Wentzel Larsen T, Aarsland D. Changes in motor subtype and risk for incidental dementia in Parkinson’s disease. *Mov Disord*. (2006) 21:1123–30. doi: 10.1002/mds.20897

26. Berg D, Postuma RB, Bloem B, Chan P, Dubois B, Gasser T, et al. Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson’s disease. *Mov Disord*. (2014) 29:545–62. doi: 10.1002/mds.25844

27. Fereshtehnejad SM, Romenets SR, Anang JB, Latreille V, Gagnon JF, Postuma RB. New clinical subtypes of parkinson disease and their longitudinal progression: a prospective cohort comparison with other phenotypes. *JAMA Neurol*. (2015) 72:863–73. doi: 10.1001/jamaneurol.2015.0703

28. Fereshtehnejad SM, Zeighami Y, Dagher A, Postuma RR. Clinical criteria for subtyping Parkinson’s disease: biomarkers and longitudinal progression. *Brain*. (2017) 140:1959–76. doi: 10.1093/brain/awx118

29. Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. *Mov Disord*. (2004) 19:1020–8. doi: 10.1002/mds.20213

30. Otsuka M, Ichiya Y, Kuwabara Y, Hosokawa S, Sasaki M, Yoshida T, et al. Differences in the reduced 18F-Dopa uptakes of the caudate and the putamen in Parkinson’s disease: correlations with the three main symptoms. *J Neurol Sci*. (1996) 136:169–73.

31. Rodriguez-Oroz MC, Jahanshahi M, Krack P, Litvan I, Macias R, Bezard E, et al. Initial clinical manifestations of Parkinson’s disease: features and pathophysiological mechanisms. *Lancet Neurol*. (2009) 8:1128–39. doi: 10.1016/S1474-4422(09)70293-5
32. Benamer HT, Patterson J, Wyper DJ, Hadley DM, Macphee GJ, Grosset DG. Correlation of Parkinson's disease severity and duration with 123I-FP-CIT SPECT striatal uptake. *Mov Disord.* (2000) 15:692–8.
33. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. *Neurobiol Aging.* (2003) 24:197–211.
34. Burke RE, Dauer WT, Vonsattel JP. A critical evaluation of the Braak staging scheme for Parkinson's disease. *Ann Neurol.* (2008) 64:485–91. doi: 10.1002/ana.21541
35. Rascol O, Fitzer-Attas CJ, Hauser R, Jankovic J, Lang A, Langston JW, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. *Lancet Neurol.* (2011) 10:415–23. doi: 10.1016/S1474-4422(11)70073-4
36. Olanow CW, Rascol O, Hauser R, Feigin PD, Jankovic J, Lang A, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. *N Engl J Med.* (2009) 361:1268–78. doi: 10.1056/NEJMoa0809335

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Lee, Song, Kim, Ku and Lee. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.